Premium
Aberrant p53 alters DNA damage checkpoints in response to cisplatin: Downregulation of CDK expression and activity
Author(s) -
Wrighton Katharine H.,
Prêle Cecilia M.,
Sunters Andrew,
Yeudall W. Andrew
Publication year - 2004
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.20446
Subject(s) - cisplatin , propidium iodide , dna damage , apoptosis , biology , cyclin dependent kinase , cancer research , microbiology and biotechnology , cyclin a , cell cycle , cyclin b1 , cell cycle checkpoint , cyclin dependent kinase 1 , programmed cell death , dna , biochemistry , genetics , chemotherapy
The p53 tumor suppressor protein is a critical mediator of cell cycle arrest and apoptosis in response to genotoxic stress. Abrogation of p53 function is a major feature of tumor development and may result in a compromised DNA‐damage response. In our study, we examined the effect of expressing a human p53 cDNA, encoding a histidine to leucine amino acid substitution at codon 179 (H179L), on the ability of wild‐type p53‐containing NIH3T3 cells to respond to treatment with the chemotherapeutic cisplatin. After 72 hr of cisplatin treatment control cells underwent apoptosis preceded by a combination of S‐ and G 2 arrest, as judged by flow cytometry of propidium iodide‐stained cells, and TUNEL and caspase‐3 assays. This correlated with increased expression of the pro‐apoptotic protein Bax. In contrast, cells stably expressing H179L‐p53 arrested in S‐phase following cisplatin treatment, which correlated with a marked decrease in the expression of cdc2, cyclin B1 and cyclin A, and a decrease in CDK2 and cyclin A‐associated kinase activity. Interestingly, H179L p53 expressing cells underwent apoptosis earlier than control cells, indicating that this aberrant p53 may enhance cisplatin chemosensitivity. These data suggest that dominant‐negative p53 can influence the expression and activity of CDK complexes, thereby modifying cell behavior following cisplatin‐induced genotoxicity. © 2004 Wiley‐Liss, Inc.